A stratified adaptive two-stage design with co-primary endpoints for phase II clinical oncology trials

被引：0
|
作者：
Bastien Cabarrou
Eve Leconte
Patrick Sfumato
Jean-Marie Boher
Thomas Filleron
机构：
[1] Institut Claudius Regaud - IUCT-O,Biostatistics & Health Data Science Unit
[2] University of Toulouse Capitole,Toulouse School of Economics
[3] Institut Paoli-Calmettes,Biostatistics Unit
[4] Aix Marseille Université,undefined
[5] INSERM,undefined
[6] IRD,undefined
[7] SESSTIM,undefined
来源：
BMC Medical Research Methodology | / 22卷
关键词：
Phase II clinical oncology trials; Heterogeneity; Adaptive stratified design; Co-primary endpoints;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] A stratified adaptive two-stage design with co-primary endpoints for phase II clinical oncology trials
    Cabarrou, Bastien
    Leconte, Eve
    Sfumato, Patrick
    Boher, Jean-Marie
    Filleron, Thomas
    [J]. BMC MEDICAL RESEARCH METHODOLOGY, 2022, 22 (01)
  • [2] A two-stage design with two co-primary endpoints
    Song, James X.
    [J]. CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2015, 1 : 2 - 4
  • [3] Optimal Two-Stage Design for the Phase II Cancer Clinical Trials With Responses and Early Progression as Co-primary Endpoints
    Tan, Xianming
    Takahara, Glen
    Tu, Dongsheng
    [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2010, 2 (03): : 348 - 354
  • [4] Estimation of the binomial probabilities in a two-stage phase II clinical trial with two co-primary endpoints
    Sun, Yiming
    Zhang, Xinyi
    Tan, Xianming
    Tu, Dongsheng
    [J]. CONTEMPORARY CLINICAL TRIALS, 2021, 105
  • [5] Estimation of secondary endpoints in two-stage phase II oncology trials
    Kunz, Cornelia Ursula
    Kieser, Meinhard
    [J]. STATISTICS IN MEDICINE, 2012, 31 (30) : 4352 - 4368
  • [6] A two-stage patient enrichment adaptive design in phase II oncology trials
    Song, James X.
    [J]. CONTEMPORARY CLINICAL TRIALS, 2014, 37 (01) : 148 - 154
  • [7] A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials
    Sill, Michael W.
    Rubinstein, Larry
    Litwin, Samuel
    Yothers, Greg
    [J]. CLINICAL TRIALS, 2012, 9 (04) : 385 - 395
  • [8] Optimal, minimax and admissible two-stage design for phase II oncology clinical trials
    Fei Qin
    Jingwei Wu
    Feng Chen
    Yongyue Wei
    Yang Zhao
    Zhiwei Jiang
    Jianling Bai
    Hao Yu
    [J]. BMC Medical Research Methodology, 20
  • [9] Optimal, minimax and admissible two-stage design for phase II oncology clinical trials
    Qin, Fei
    Wu, Jingwei
    Chen, Feng
    Wei, Yongyue
    Zhao, Yang
    Jiang, Zhiwei
    Bai, Jianling
    Yu, Hao
    [J]. BMC MEDICAL RESEARCH METHODOLOGY, 2020, 20 (01)
  • [10] Evaluating Co-primary Endpoints Collectively in Clinical Trials
    Li, Qian H.
    [J]. BIOMETRICAL JOURNAL, 2009, 51 (01) : 137 - 145
12345